Drug Trial Radar · NCT07275788
A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jan 8, 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Regend TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Shanghai Tongji Hospital, Tongji University School of Medicine
- First posted
- Dec 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
REGEND003, which consists of human kidney progenitor cells, demonstrates promising potential in repairing kidney injury. The purpose of this study is to assess the saftey and tolerability of REGEND003 on patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. It is an exploratory study with multi-centered, randomized, controlled, single-blinded, dose-escalated designs.
Conditions
- Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
Interventions
REGEND003Biological
REGEND003
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event (AE) associated with the Cell TherapyTime frame: Within 24 weeks post-treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Tongji Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.